Crescent Energy to acquire Vital Energy in all-stock transaction

Crescent Energy Company has signed a final agreement to gain biological energy in a $ 3.1 billion -shares deal, including net VITAL debt.

This integration was set to enhance the Crescent Energy position in the energy sector through a strategy that focuses on consistent and free cash flow, size size and allocating flexible capital in the leading basins.

Litage shareholders, with the presence of the conditions of integration, will receive 1.9062 of regular shares of Crescent Class per share of vitality they keep, equivalent to 5 % higher than the average trading price for 30 days on August 22, 2025.

This merger is valuable to all shareholders through the return on cash investment on cash, which is supported by the evaluation caused by the current production institution.

The deal is expected to enhance the free cash flow, the cash flow from the operations and the net value of the assets per share, with an immediate annual costume ranging between 90 million dollars and 100 million dollars, as well as the prospects for additional operational efficiency.

Crescent plans to publish a business model that prefers decreased activity and increasing free cash flow, ensuring that its assets are compatible with its strategic goals and enhancing shareholders ’revenues with leading profit distributions between its peers.

The transaction has been set to create the largest fluid product without a degree of investment, with the use of a $ 1 billion pipeline and pipeline.

It also provides a fixed investment and operational insurance, which includes opportunities worth more than $ 60 billion in a joint imprint.

The asset portfolio will be decreased and concentrated, which features adaptive capital distribution over more than ten years of stock quality in Eagle Ford, Permian and Uinta.

“Getting a vital pipeline and implementing an attractive pipeline from non -essential disposal operations sharpens our focus and expands our specific opportunities for future growth.”

Hilal shareholders, upon completion, are scheduled to have about 77 % of the integrated entity, while vital shareholders will own about 23 % on a completely diluted basis.

The boards of directors of the two companies agreed to the treatment unanimously, with the presence of a special committee for the independent Hilal directors, and also submitted approval unanimously.

The shareholders who represent about 29 % of the crescent, 20 % of the vitality entered the vote and/or current investor agreements to support treatment.

Taking into account the usual closure conditions that include the crescent, vital shareholders and regulatory agencies, the transaction is expected to be closed by the end of this year.